{
  "id": 1878029,
  "title": "BioMarin to acquire Alesta Therapeutics for up to $490 million",
  "url": "https://urgent.news/2026/08/19/biomarin-to-acquire-alesta-therapeutics-for-up-to-490-million",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-19T06:03:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/biomarin-to-acquire-alesta-therapeutics-for-up-to-490-million-93CH-4866458"
  },
  "original_language": "en",
  "account": "BioMarin Pharmaceutical Inc. is set to acquire Alesta Therapeutics, a clinical-stage biotechnology company, in a deal potentially worth up to $490 million. The agreement, announced via press release from RTW Biotech Opportunities Ltd, includes an upfront payment of $275 million for Alesta's lead asset, ALE1. This small-molecule therapy is in development for hypophosphatasia, a rare genetic disorder impacting bone and tooth mineralization, leading to fractures, tooth loss, muscle weakness, fatigue, and pain.\n\nThe total transaction value may exceed $490 million, contingent on additional milestone payments. Upon closing, Alesta will spin off all non-ALE1 assets into a separately formed entity, retaining proportional ownership in this new company. BioMarin's July 31, 2026 valuation of RTW Bio's shares in Alesta increased by 41%, adding $1.6 million to its net asset value. This acquisition marks the sixth within 2026 from RTW Bio's portfolio, following investments by major pharmaceutical companies like Boston Scientific, GSK, Biogen, Eli Lilly, and AbbVie.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}